共 131 条
[11]
Comelli F(2017)Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis Pain. 158 2442-13
[12]
Giagnoni G(2000)Feldmann Met al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Proc Natl Acad Sci U S A. 97 9561-246
[13]
Colleoni M(2017)Walsh SLet al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers Drug Alcohol Depend. 172 9-226
[14]
Kumar RN(2019)Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects F1000Res 8 F1000-242
[15]
Chambers WA(2006)A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med Hypotheses. 66 234-218
[16]
Pertwee RG(2016)Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice Eur Neurol 76 216-449
[17]
Pacher P(2018)The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews Curr Neurol Neurosci Rep 18 8-188.e1
[18]
Bátkai S(2016)Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study Neurol Sci 37 235-220
[19]
Kunos G(2013)An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics J Pain Symptom Manage. 46 207-52
[20]
Zou S(2012)Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial J Pain 13 438-335